Core Insights - Bionano Laboratories announced a preliminary payment determination from CMS for a new CPT code for optical genome mapping (OGM) in detecting genetic disorders, priced at $1263.53, which is higher than existing microarray codes [1][2][3] Group 1: CPT Code and Pricing - The new Category I CPT code for OGM will facilitate reimbursement for laboratory developed tests (LDTs) based on OGM, providing a pricing advantage over traditional methods [2][3] - The new CPT code 81354 for constitutional genetic disease analysis is expected to be priced at $1263.53, which is $363.53 higher than code 81228 and $103.53 higher than code 81229 [1][2] Group 2: Clinical Applications and Impact - OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV are expected to be covered under the new CPT code, indicating their relevance in clinical settings [2][3] - The introduction of this CPT code is anticipated to enhance awareness and support for OGM in both oncology and clinical genetic testing communities globally [3] Group 3: Company Overview - Bionano Laboratories, a subsidiary of Bionano Genomics, specializes in CLIA-certified LDTs utilizing OGM technology to advance genetic diagnostics [4][5] - The company aims to transform genome analysis through innovative solutions and diagnostic services, including OGM and related software [5]